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CitrateanticoagulationhasrisenininterestsoitisnowarealalternativetoheparinintheICUspractice.Citrateprovidesaregional
anticoagulation virtually restricted to extracorporeal circuit, where it acts by chelating ionized calcium. This issue is particularly
true in patients ongoing CRRT, when the “continuous” systemic anticoagulation treatment is per se a relevant risk of bleeding.
Whencomparedwithheparinmostofstudieswithcitratereportedalongercircuitsurvival,alowerrateofbleedingcomplications,
andtransfusedpackedredcellrequirements.AsanticoagulantforCRRT,theinfusionofcitrateisprolongedanditcouldpotentially
have some adverse eﬀects. When citrate is metabolized to bicarbonate, metabolic alkalosis may occur, or for impaired metabolism
citrate accumulation leads to acidosis. However, large studies with dedicated machines have indeed demonstrated that citrate
anticoagulation is well tolerated, safe, and an easy to handle even in septic shock critically ill patients.
1.Introduction
Multiple technological advancements aﬀecting continuous
renal replacement therapy (CRRT) delivery to critically ill
patients have been developed in the past twenty years.
Dedicated CRRT equipment with better thermal control,
more precise balances and volumetric control of infused and
ﬁltered ﬂuids, and user friendly machines now allow a safe
CRRT provision, which has become increasingly popular.
Generally speaking, the practical background of con-
tinuous treatment feasibility in critically ill patients, often
hemodynamically instable, septic, or suﬀering from trauma
orrecent surgery,is closed tothe need foranticoagulation.In
eﬀect, systemic anticoagulation is still the main challenge in
the application of CRRT, since it exposes the patient to a risk
of active bleeding episodes.
Heparin, ﬁrst adopted as an anticoagulant in the late
1920s, made feasible the patency of extracorporeal circuits,
and nowadays it remains the most popular anticoagulant
worldwide used in extracorporeal dialysis [1]. Heparin is the
drug of choice in chronic patients undergoing hemodialysis
as well as in acute patients treated by CRRT. Heparin is
eﬃcient and instantaneous in its anticoagulation, quite safe
and cheap so that heparin can be administered with ease to
patients.
Bleeding is the main side eﬀect of i.v. heparin adminis-
tration for CRRT. The incidence of bleeding episodes con-
sidering all of the administration methods ranges from 10%
to 50%, with a bleeding mortality rate as high as 15% [2–4].
Hepariniscontraindicatedincriticallyillpatientswithactive
bleeding or at high risk of bleeding, as seen in such patients
with extensive trauma, burns, or in surgery patients [2].
As alternative to heparin, several methods of systemic
or regional anticoagulation have been proposed over the
past 50 years, including low-molecular weight heparin,
prostacyclin, the serine proteinase inhibitor nafamostat,
hirudin, regional heparinization, saline ﬂushes, and regional
citrate anticoagulation. Among these, citrate anticoagulation
has risen in interest so it is now a real alternative to heparin








Figure 1: Scheme of standard citrate anticoagulation in CVVHDF.
2. Regional CitrateAnticoagulationas
AlternativetoHeparin
Citrate was ﬁrst reported as an anticoagulant for hemodial-
ysis in 1960s by Morita et al. [5] and as an alternative
regional anticoagulation in patients ongoing CRRT in 1990
by Metha et al. [6]. Since then, citrate has gained more
and more popularity. Regional citrate anticoagulation has
beenutilizedinCRRTprogrammesbasedonitsfundamental
properties of avoiding a systemic anticoagulation. Citrate
provides a regional anticoagulation virtually restricted to
extracorporeal circuit, where it acts by chelating ionized
calcium. This issue is particularly true in patients ongoing
CRRT, when the “continuous” systemic anticoagulation
treatment is per se a relevant risk of bleeding.
However, citrate use is not uniform, and it has been
utilized mainly in North America and Europe CRRT pro-
grammes. For instance, anticoagulation with a regional
citrate or systemic heparin standardized protocol for CRRT
has been implemented since 1999 in all adult ICUs patients
in Canadian Calgary Health Region [7]. Based on a North
American survey, it has been estimated that a quarter of all
patients suﬀering from acute kidney injury (AKI) are treated
with CRRT, and regional citrate anticoagulation has been
used as method of choice in only 13% of these patients [8].
In a recent survey on all ICUs practice in North-West of Italy
(covering a population of 4.5 millions of inhabitants), in the
vastmajorityofdialysissessionsdonein2007unfractionated
heparin was the anticoagulant of choice (5,296 out of
7,842 dialysis sessions, 67.5%). Interestingly, on patients
at high risk of bleeding regional citrate anticoagulation
was performed only in 18.0% of the cases, whereas the
principle treatment modality remained that of a dialysis
session without heparin, or at low heparin doses with saline
ﬂushes (77.6%) [9]. However, it is reasonable to presume
that the use of citrate will grow in popularity in the near
future. The inherent complexities of the method are now
reduced since RRT dedicated monitor may indeed provide
a safe and an easy-to-handle citrate anticoagulation protocol
besides standard heparin anticoagulation [10].
3.CitrateActs by Reducing IonizedCalcium
(iCa++) Concentration
As anticoagulant, citrate has been applied to hemodialysis,
hemodiaﬁltration (in pre/postdilution), hemoﬁltration (in
pre-postdilution), sorbent technology and in both contin-
uous and intermittent treatments [4, 6, 7, 11–20]. By a
Medline search more than 60 diﬀerent systems for citrate
administration can be found. Most of these systems have
been home made with its speciﬁc composition of ﬂuids,
and its own rules to provide anticoagulation and titrate
calciumadministration.Inthelastyearsglobalcitratemarket
has been deeply changing. Dialysis machines for CRRT
have incorporated citrate anticoagulation in the soft- and
hardware, as well as dedicated ﬂuids have been certiﬁed and
registered by industries.
However, as shown in Figure 1 all citrate systems present
in the market work on few simple and shared modalities:
(1) preﬁlter infusion of citrate, which acts as chelat-
ing ionized calcium (an iCa concentration below
0.35mmol/L is required to inhibit coagulation);
(2) dialysate (and predilution or postdilution if present)
ﬂuids are calcium free;
(3) a replacement infusion of calcium at the end of
extracorporeal circuit, in the blood line returning to
patient.
As part of mechanisms operating during citrate antico-
agulation, in the ﬁlter citrate-calcium complex and iCa++
are partially cleared by convection and/or diﬀusion, since
membranes currently used in CRRT have a sieving coeﬃ-
cients near to unit for these small molecules. The remaining
amount of citrate not cleared by ﬁlter enters the systemic
circulation, and should be metabolized. As a consequence of
the use of calcium free ﬂuids, citrate anticoagulation leads
to a net loss of calcium by ﬁlter. In the patient iCa++ rises
again by replacement infusion of calcium at the end of
circuit and the liberation of chelated calcium when citrate
is metabolised.
4. Efﬁcacy andSafety of Citrate
4.1. Circuit Survival. In respect to heparin, citrate is emerg-
ing as being similar or even superior as anticoagulant in
terms of ﬁlter life and eﬃcacy of anticoagulation. Factors
inﬂuencing the circuit life reﬂect in part the coagulation
capacity of the patient (procoagulant and/or anticoagulant
factors due to acute illness, platelet count) and in part the
technical aspects of dialysis (diﬀusion/convection modality,
ﬁltration fraction, pre- postdilution, vascular access quality,
blood ﬂow rate, nursing monitoring of dialysis).
In addition, citrate anticoagulation could be modulated
by the target of citrate concentration reached in circuit blood
(from 3 to 5mmol/L of citratemia). As increased levels of
anticoagulation could be obtained according to increased
dose of heparin, a level of citratemia of 5mmol/L (according
to a concentration of iCa++ below 0.1mmol/L) leads to a
total and persistent inability of blood coagulation.International Journal of Nephrology 3
Most of studies reported longer circuit survival with cit-
rate, but only few studies comparing citrate to heparin were
randomized [13, 14, 21–23]. Circuit life was signiﬁcantly
longer with citrate [13, 14, 23], while circuit life was similar
in the other 2 [21, 22]. As a matter of fact, blood citrate
concentration of around 4mmol/L is adapted to achieve
excellent ﬁlter run times. Some trials who found that citrate
did not achieve better ﬁlter run time used a blood citrate
concentration of 3mmol/L, and often did not control the
ionized postﬁlter calcium values [21].
In a prospective, randomized clinical trial, Monchi et
al. compared unfractionated heparin and regional citrate
anticoagulation in 20 CVVH patients [13]. They found
a median circuit life of 40h with heparin and 70h with
citrate (heparin adjusted to get an APTT at 60–80 s, citrate
infusion adjusted to maintain circuit iCa++ <0.3mmol/L).
Similarly, a prospective randomized study involving 30
patients undergoing CVVHDF not at high risk of hemor-
rhagic complications showed a median hemoﬁlter survival
time of 124.5 hours in the citrate group and 38.3 hours
in the heparin group (P<. 001) [22]. Heparin dose was
adjusted to obtain an APTT at 45–65s, citrate infusion
to maintain circuit iCa++ between 0.25–0.35mmol/L. In a
recent prospective randomized multicenter trial Hetzel et al.
[23] compared in CVVHF in total predilution citrate with
heparin. Mean hemoﬁlter patency was signiﬁcantly longer
in the HF-Citrate group compared with the HF-bicarbonate
group (37.5 ± 23h versus 26.1 ± 19h, P<. 001, n =
87/81).
In contrast, in other 2 randomized trials citrate was
not superior to heparin in circuit survival [21, 22]. In a
large multi-center study involving seven USA centers, 138
patients and 442 CRRT circuits were studied to assess ﬁlter
life span and anticoagulation complications with anticoagu-
lation based on heparin, citrate, or with no anticoagulation
[15]. Mean circuit survival was not diﬀerent for circuits
receiving heparin (42.1 ± 27.1h) and citrate (44.7 ± 35.9h),
with similar clotting rates and without any signiﬁcant
diﬀerence by Kaplan-Meier analyses of survival between the
two groups. Circuits without anticoagulation presented a
signiﬁcant lower survival (27.2 ± 21.5h, P<. 001).
In another study of 87 patients undergoing CRRT from
the Calgary Health Region, Canada, 54 were initially treated
with citrate (212 ﬁlters), 29 with heparin (97 ﬁlters), and 4
withsalineﬂushes[7].Medianﬁlterlifespanwassigniﬁcantly
higher with citrate than with UFH (40 hours versus, 30
hours, P<. 001) [7].
Finally, in 70 severe burn patients with septic shock
treated by continuous or intermittent HDF with citrate or
heparin anticoagulation, circuit survival was signiﬁcantly
longer with citrate on continuous treatment but not in
intermittent modality [24].
4.2. Bleeding Complications. The primary reason to use
citrate is that it leads to a regional anticoagulation, virtually
restricted to extracorporeal circuit. Therefore, citrate anti-
coagulation does not increase patient risk of bleeding. In
addition citrate is speciﬁcally indicated in patient at high risk
of bleeding.
The 5 available randomized studies comparing heparin
to citrate enrolled patients excluding those at high bleeding
risk [13, 14, 21–23].
However, bleeding episodes were similar with citrate and
h e p a r i ni nt w or e p o r t s[ 13, 21] and reduced with citrate in
other two [14, 22, 23] .N od e ﬁ n i t eh e m o r r h a g ei nt h ec i t r a t e
group and seven instances in the heparin group and one
occult hemorrhage in both citrate and heparin groups were
observed [14]. After adjustment for antithrombin-III levels
andillnessseverityscore,therelativeriskofhemorrhagewith
citrate anticoagulation was still signiﬁcantly lower than that
with heparin (0.14 versus 0.96). Even if citrate was used in
presenceofalowersystemicanticoagulationwithheparin(at
meandoseof5,428UI/day),bleedingcomplicationsepisodes
(5.7%) were signiﬁcantly lower in comparison with heparin
(14.5% episodes, at mean heparin dose of 13,174UI/day)
[23].
Similarly, the number of transfused packed red cells per
day with citrate was similar to those with heparin in 3 studies
[14, 21, 22], whereas in CVVHF study by Monchi et al. [13]
wassigniﬁcantlyreduced(1.0transfusedpackedredcells/day
in heparin group and 0.2 in citrate group).
In the multi-center study involving 138 patients and 442
CRRT circuits, life-threatening bleeding complications as a
result of the anticoagulant were shown in 9 patients in the
h e p a r i ng r o u pa n da b s e n ti nc i t r a t eg r o u p[ 15]. In the same
way,inastudyof87patientsundergoingCRRTfromCalgary
Health Region citrate anticoagulation was well tolerated, and
no treatment was discontinued for hemorrhagic episodes
[7].
In70severeburnpatientswithsepticshockandAKI,and
undergoing RRT, bleeding complications were signiﬁcantly
lower with citrate during CVVHDF, as well as the require-
ments of transfused packed red cells per day (1.76 transfused
packedredcells/daywithheparingroupand0.98withcitrate
group) [24].
4.3. Citrate Anticoagulation in Critically Ill Patients Treated
with Sorbent Technology. Sorbent technology is a promis-
ing tool for extracorporeal techniques targeted to remove
detrimental substances present in blood of septic shock
patients. Sorbents have speciﬁc characteristics, such as an
access to substances bound to protein, a removal capacity of
larger molecular weight toxins exceeding cut-oﬀ of dialysis
membranes. In addition, in the future many advances in
resin sorbent technology will come out.
As anticoagulant, citrate has been demonstrated to be
safe and eﬃcient in septic shock patients treated by sorbent
technology [25]. In 13 severe burn and polytrauma patients
at high risk or with active bleeding and treated with plasma
adsorption, 58 sessions using systemic anticoagulation with
heparin (mean heparin 741U/h) were compared with 28
sessions using citrate regional anticoagulation (circuit cit-
ratemia at 4mmol/L) evaluating eﬃciency and safety of
the technique. Plasma ﬁltration eﬃciency and number of
used cartridges were similar, whereas the number of lost
cartridges was signiﬁcantly lower in the citrate patients
[25].4 International Journal of Nephrology
5. MetabolicConsequences and
ToleranceofCitrate
When administered intravenously in healthy subjects citrate
is rapidly metabolized to bicarbonate by the tricarboxylic
pathway in liver, kidney, and skeletal muscle. In addition,
at high serum levels a substantial percentage of citrate is
excreted unchanged in the urine [26]. Citrate can also be
involved in many other biochemical pathways including
amino acid synthesis and gluconeogenesis [26].
In presence of chronic renal failure citrate metabolism
may be impaired. Both loss of metabolically active kid-
ney mass and accumulation of soluble toxins can aﬀect
some metabolic pathways in extrarenal tissues. In addition,
liver metabolism of gluconeogenetic intermediates and the
tricarbonic acid cycle are impaired in uremic state [27].
Investigating the metabolism of citrate in patients on regular
hemodialysis and minimal residual renal function (urinary
output < 400mL/d), Bauer et al. [27] did not observe alka-
linization or pH variation after sodium citrate i.v. infusion.
When used for regional anticoagulation of the dialysis
circuit in CRRT, the infusion of citrate is prolonged, and
i tm a yh a v es o m ea d v e r s ee ﬀects. Citrate is an organic
compound able to react with divalent cations such as
magnesium and calcium. By chelating calcium citrate blocks
coagulation activation in the dialysis circuit. As citrate is
metabolized to bicarbonate, metabolic alkalosis may occur
or, in contrast, if citrate is not metabolized and accumulates,
acidosis can develop. Moreover, since citrate is usually
applied as trisodium citrate it can lead to excessive sodium
load and hypernatremia. Hypomagnesemia may be another
consequence but, at our knowledge, no case of severe
hypomagnesemia has been reported.
In 1997 Palsson and Niles [11] reported 2 cases of
citrate accumulation and refractory systemic hypocalcemia
using a simpliﬁed protocol with preﬁlter citrate infusion
during CVVHF in 15 patients. More recently by using the
same protocol as citrate as the only buﬀer substance Hetzel
et al. [23] found equivalence of standard bicarbonate in
groups HF-citrate and HF-bicarbonate from day 3 to day
11. However, more patients in the HF-citrate group needed
additional bicarbonate infusions compared with the patients
treated with heparin.
In a large single-center analysis of 209 patients (37
received citrate as sole anticoagulant, 87 low-dose heparin
plus citrate, and 85 only heparin), a development of
metabolic alkalosis in 50% of patients treated with citrate
was observed [18], and all cases were solved by increasing the
dialysate ﬂow rate.
Three recently controlled large studies [7, 14, 15],
involving a total of 251 patients and comparing citrate
(121 patients) with heparin anticoagulation in CRRT in
critically ill patients, conﬁrmed the safety of the citrate. In
138patientsand442CRRTcircuits,outof37patientstreated
with citrate, metabolic alkalosis was shown in 4 cases and
citrate accumulation in 2 patients with liver failure but they
were all managed by decreasing infusion rate of bicarbonate
containing solution or of citrate [15]. Generally speaking,
citrate anticoagulation was well tolerated, and no treatment
was discontinued for hypernatremia, metabolic alkalosis,
hypocalcemia, or citrate accumulation. A safe and an easy-
to-handlecitrateanticoagulationprotocolnowcommercially
available has been recently validated in 162 patients [20].
This protocol provided an excellent acid base and electrolyte
control in critically ill patients with acute renal failure,
allowing a wide spectrum of treatment doses.
Liver is the most important organ in citrate metabolism.
Kramer et al. [28] showed that in intensive care patients
liver citrate clearance is decreased by approximately 50% in
patients with cirrhosis compared with normal liver function.
In cirrhotic patients impairment of citrate metabolism
can cause citrate increase and hypercalcemia due to an
accumulation of calcium-citrate complexes [28].
When citrate-calcium complexes increase in circula-
tion, systemic iCa++ concentration decreases and the ratio
between total to ionized calcium increases [29]. Ratio has
been used as an indirect parameter of blood citrate increase.
However, this ratio may not predict citrate accumulation in
all cases [28, 30].
Ar e c e n ts t u d y[ 24] involving 31 severe burn patients
undergoing CVVHDF or SLED-HDF with citrate regional
anticoagulation showed a good metabolic tolerance. Sys-
temic arterial pH, Na+,K +,i C a ++,t o t a lC a ++/iCa++ ratio
and bicarbonates did not show any derangements over
the period of observation. Citrate was determined directly
dosing systemic citratemia and the levels of citrate in the
ultraﬁltrate. During the CRRT a high portion of the citrate-
calcium complexes were lost in eﬄuent (membranes cur-
rentlyusedwerehighlypermeabletofreeandcalcium-bound
citrate, with a sieving coeﬃcients near to unit). The marked
loss of citrate (up to 60% of the infused amount) directly
correlated with eﬄuent volume. By increasing dialysate ﬂow
rate, citrate loss could be increased [24] and decreased the
remaining amountofcitrate-calciumcomplexes returningto
the patient.
Oudemans-van Straaten [21] recently compared the
safety and eﬃcacy of citrate with the nadroparin anti-
coagulation in 200 patients (97 treated with citrate) on
CRRT. As it concerns tolerance citrate was superior to
low-molecular weight heparin. Nadroparin patients more
frequently developed metabolic alkalosis, hyponatremia and
hyperlactatemia, whereas initial hypocalcemia was less often
correctedinthecitratepatients.Unexpectedly,citrateseemed
to improve patient and kidney survival (three-month mor-
tality was 48% with citrate versus 63% with nadroparin).
Citrate appeared particularly beneﬁcial in the subgroups of
patients after surgery, with sepsis or with severe multiple
organ failure [21]. However, favourable data about mortality
are not conﬁrmed in more recent multicenter randomized
trial [23]. Sepsis was the predominant reason for death
in both studies [21, 23], and exposure to citrate was
considerably longer (8.5 days versus 2.7 days) in the trial
without any favourable eﬀect on mortality [23].
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